Market Access Reality Check for Disease Modifying AD Drugs
- CMS coverage gap for pre clinical anti amyloids and spill over to private payers
- Cost drivers: MRI monitoring, infusion logistics and diagnostic bundling
- Generating evidence packages that HTA bodies prioritise (QoL, caregiver, budget impact) with responsible data storytelling to maintain policymaker trust